retatrutide clinical trial phase retatrutide First 3 data for are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and Triple hormone receptor agonist retatrutide
Description
These symptoms are typically mild to moderate in severity and tend to diminish over time as the body adjusts to the medication, particularly when dose escalation follows the recommended gradual schedule
Source: PharmaProjects
E.MatthayM
2021 Jun;81(8):881-893
Hims & Hers also includes educational content on managing side effects and maximizing results from GLP-1 treatment
Office visits are covered by TFL
